The prime-boost strategy: exciting prospects for improved vaccination

Ramshaw, Ian A.; Ramsay, Alistair J.

doi:10.1016/s0167-5699(00)01612-1

Cited by 327 publications

(186 citation statements)

References 16 publications

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…To this end, we plan to examine the use of a prime-boost strategy, which is known to greatly increase the potency of DNA vaccinations. 38,39 Previously Dresch et al 13 have showed that lentiviral vector containing the 5 0 untranslated region of DC-STAMP yields long-term, DC-specific OVA expression in vivo. Moreover, their work confirms our data with respect to DC-STAMP promoter.…”

Section: Discussionmentioning

confidence: 99%

Targeting dendritic cells with antigen via dendritic cell-associated promoters

et al. 2012

View full text Add to dashboard Cite

The induction of tumor-specific immune responses is largely dependent on the ability of dendritic cells (DCs) to present tumor-associated antigens to T lymphocytes. Therefore, we investigated the use of DC-associated promoter-driven genetic vaccines to specifically target DC in vivo. Restricted expression of vaccine-encoding genes in DC should enhance specificity and improves their safety for clinical applications. Hereto, 3 --5 kb upstream sequences of the murine genes encoding CD11c, DC-SIGN, DC-STAMP and Langerin were isolated, characterized and subcloned into enhanced green fluorescent protein (EGFP) reporter constructs. Upon electroporation, EGFP was expressed in DC cell lines, but not in other cell lines, confirming DCrestricted promoter activity. When these promoters were cloned into a construct upstream of the gene for ovalbumin (OVA), it appeared that DC-STAMP promoter-driven expression of OVA (pDCSTAMP/OVA) in DC yielded the most efficient OVA-specific CD4 þ and CD8 þ T-cell responses in vitro. Administration of pDC-STAMP/OVA in vivo, using the tattoo gun vaccination system, evoked specific immune responses as evidenced in a mouse tumor model. Adoptively transferred pDC-STAMP/OVA-transfected DCs induced strong CD8 þ T-cell proliferation in vivo. These experiments demonstrate that our DC-directed promoter constructs are potential tools to restrict antigen expression in DC and could be implemented to modulate DC function by the introduction of relevant proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting dendritic cells with antigen via dendritic cell-associated promoters

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Strategies to overcome this problem include prime -boost protocols that vary from immunizations once every week to once every 3 months. 105,106 What then are the requirements that a possible therapeutic vaccine against an established tumor has to fulfill? Experiments using DC that constitutively express the LCMV-GP33 for immunization protocols against tumors 53,107 but also for the induction of diabetes in the RIP -GP model 50 highlighted the importance of a continuous presence of antigen within lymphoid organs for at least 7-14 days.…”

Section: Cancer Gene Therapymentioning

confidence: 99%

“…This limitation has led to the concept of cycling different viral vectors in prime -boost protocols. 106 Indeed, a marked enhancement of immunization potency has been observed with prime-boost protocols using different recombinant viruses, e.g., fowlpox followed by vaccinia virus. 122 Taken together, an ideal viral vector for tumor immunotherapy should combine prolonged persistence and replication in vivo with minimal risk for disease induction in the patient and horizontal spread -a goal that is difficult to reach.…”

Section: Viral Vectors For the Induction Of Antitumor Immunitymentioning

confidence: 99%

Principles of tumor immunosurveillance and implications for immunotherapy

Ochsenbein

2002

Cancer Gene Ther

View full text Add to dashboard Cite

Although antigen loss variants, major histocompatibility ( MHC ) class I down -regulation, or the expression of inhibitory molecules may explain the failure of immunosurveillance against some tumors, this seems not to apply for many other solid peripheral or lymphohematopoietic tumors. Why then is immunosurveillance so ineffective and can it be improved? This review focuses on one important aspect of tumor immunity, namely the relevance of antigen dose and localization. Immune responses in vivo are induced in organized lymphoid tissues, i.e., in lymph nodes and spleen. The antigen dose that reaches secondary lymphoid organs over time is a crucial parameter that drives antiviral and antitumoral immune responses. Tumors use various strategies to prevent efficient presentation of their antigens in lymphoid organs. A major obstacle to the induction of an endogenous tumor -specific cytotoxic T lymphocyte ( CTL ) response is the inefficient presentation of tumor antigen on MHC class I molecules of professional antigenpresenting cells. Peripheral solid tumors that develop outside lymphoid organs are, therefore, often ignored by the immune system. In other situations, tumors -especially of lymphohematopoietic origin -may tolerize specific CTLs. Understanding tumor immunosurveillance is key to the design of efficient antitumor vaccines. Attempts to improve immunity to tumors include vaccination strategies to ( a ) provide the tumor antigen to secondary lymphoid organs using recombinant viruses or dendritic cells as carriers, ( b ) express costimulatory signals on tumor cells, or ( c ) improve the efficiency of cross -priming.

show abstract

“…In addition, recombinant MVA viruses have been shown to be excellent boosters of vaccine induced immunity, particularly when DNA vaccine prime and recombinant MVA boost regimes are employed, but also when attenuated live vaccines are used as primary vaccine [46], [47] and [48].…”

Section: Introductionmentioning

confidence: 99%